Integrated pan-cancer multi-omics profiling and experimental validation identify LSM12 as a prognostic biomarker and candidate therapeutic target in human cancers

Abstract Background: RNA metabolism regulators remain insufficiently characterized across tumor types, despite the substantial expansion of multi-omics datasets. LSM12, a member of the Like-Sm (LSM) protein family involved in RNA processing, has not been systematically evaluated in a pan-cancer context. Accordingly, this study aimed to investigate the oncogenic and immunomodulatory roles of LSM12 across multiple cancer types through an integrated multi-omics framework. Methods: We conducted an integrative pan-cancer analysis using publicly available multi-omics platforms, including TIMER2, GEPIA2, TISIDB, cBioPortal, and